cagkansayin/iStock via Getty Images
- Natus Medical (NASDAQ:NTUS) to be acquired by an affiliate of ArchiMed, an investment firm focused exclusively on the healthcare industry for ~$1.2B.
- Shareholders will receive $33.50 in cash for each share of Natus (NTUS) common stock, representing a 29% premium to the closing price on April 14, 2022.
- “The sale of Natus to ArchiMed will provide our shareholders with immediate and substantial cash value, as well as a compelling premium, and the Board has unanimously agreed that this transaction is in the best interests of our shareholders,” said Joshua H. Levine, Chairman of Natus.
- Upon completion of the transaction in 3Q22, the company will become a private company and shares will no longer be listed on any public market.
- The company have the right to terminate the merger agreement with ArchiMed to enter into a superior proposal subject to the terms and conditions of such agreement.
- The company sees Q1 revenue of $119.8M, up 4.3% Y/Y vs. consensus of $115.7M.
- Due to the announced transaction, the company will no longer update financial guidance.
- Q1 results will be out after the close of the market on Thursday, May 5th.